Figure 1

Effect of sorafenib and the combinations treatments on HepG2 cancer cells. HepG2 cancer cells were seeded in 96-well plates and treated with sorafenib in presence and absence of bevacizumab, panitumumab and ramucirumab. Each value represents the meanā±āSD (nā=ā3). *Pā<ā0.05 compared to sorafenib. (A) IC50 of sorafenib at the three treatment periods calculated using GraphPad Prism software. (B) Change in sorafenib IC50 in the presence of the tested monoclonal antibodies following 24 and 48Ā h treatment periods.